Business Information
The principal activities of the group is to discover, develop and commercialize therapeutics to treat patients worldwide suffering from life-threatening diseases. It focuses its research and clinical programs on anti-infectives, antiviral, antifungal and antibacterial products. It markets Viread for the treatment of HIV infection; Ambisome, an antifungal agent; tamiflu(R) for the treatment of influenza; Daunoxome, a drug approved for the treatment of kaposi's sarcoma; Vistide for the treatment of cytomegalovirus (CMV) retinitis. It has developed liposomal drug delivery technology used to develop drugs, which are safer, easier for patients to tolerate and effective. It markets its products in the United States, the United Kingdom, Germany, Italy, Spain, France, Portugal, Greece, the Netherlands and Australia. In Jan 2003, the group acquired Triangle Pharmaceuticals Inc.
|
|
Name |
Title
|
Email
|
| Bernard Wagner | Chmn. - Scientific Advisory Board | N/A | | James Denny | Chmn. | N/A | | Anthony Caracciolo | Sr. VP - Manufacturing, Operations | N/A | | Bruce Montgomery | Sr. VP, Head - Respiratory Therapeutics | N/A | | Gregg Alton | Sr. VP, General Counsel, Sec. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 3,026,139 | (1,189,957) | | 2005 | 2,028,400 | 813,914 | | 2004 | 1,324,621 | 449,371
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
